Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-

International Archives of Medicine

Volumn 5, Issue 1, 2012, Pages

  Puertas Abreu, Eduardo ^a   Polanco, Elaudi ^b   Azocar, Miriam ^c   Mundarain, Luis ^d   Nũez Sotelo, Concepcián ^e   Montão, Rafael ^f   Vivas, Freddy ^g   Noguera, Zair ^g   Marín, Francisco ^a   Bellorin, Omar ^h   Rivas, José ^g   Toro, Eduardo ^g   Benzaquen, Eugenia ^g   Rauseo, Mayra ^d   Gutiérrez González, Luis ^g  

^a Hospital Central de Cumaná Dr Antonio Patricio de Alcalá   (Venezuela)

^b Hospital IVSS Dr Rafael Calles Sierra   (Venezuela)

^c Hospital Central de Maturín Dr Manuel Nú ez y Tovar   (Venezuela)

^d Hospital Central de Ciudad Bolívar Dr Ruiz y Páez   (Venezuela)

^e Hospital Central de Barquisimeto Dr Antonio María Pineda   (Venezuela)

^f Hospital Central de Carupano Dr Santos Anibal Dominicci   (Venezuela)

^g UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^h Hospital de la Isla de Margarita Dr Luis Ortega   (Venezuela)

Author keywords

Anti dsDNA; Anti TNF therapy; Antinuclear antibodies; Lupus like syndrome; Psoriasis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; HUMAN; INNATE IMMUNITY; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT DURATION;

EID: 84857996677     PISSN: None     EISSN: 17557682     Source Type: Journal    
DOI: 10.1186/1755-7682-5-7     Document Type: Article

References (30)

1. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Aringer M, Smolen JS, Arthritis Res Ther 2008 10 1 202 Epub 2008 Jan 23 10.1186/ar2341 18226185 (Pubitemid 352044828)
2. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F, Lupus 2005 14 12 931 937 10.1191/0961203305lu2240rr 16425572 (Pubitemid 43088266)
3. Drug insight: autoimmune effects of medications: what's new? Mongey AB, Hess EV, Nat Clin Pract Rheumatol 2008 4 3 136 144 10.1038/ncprheum0708 18200008 (Pubitemid 351338628)
4. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. Via CS, Shustov A, Rus V, et al. J Immunol 2001 15 167 6821 6826 (Pubitemid 33144173)
5. Drug-induced lupus erythematosus in a patient treated with adalimumab. Spillane AP, Xia Y, Sniezek PJ, J Am Acad Dermatol 2007 56 5 Suppl 114 S116 17434034
6. Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? Kocharla L, Mongey AB, Lupus 2008 18 169 171
7. Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab. Havel J, Aboutalebi S, Doughty L, et al. J Drugs Dermatol 2008 7 796 798 18720701
8. Treatment with tumor necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Jonsdottir T, Forslid J, van Vollenhoven A, et al. Ann Rheum Dis 2004 63 1075 1078 10.1136/ard.2003.018093 15066863 (Pubitemid 39120357)
9. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebocontrolled trials. Charles PJ, Smeenk RJ, De Jong J, et al. Arthritis Rheum 2000 43 2383 2390 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0. CO;2-D 11083258
10. Autoimmunity associated with anti-tumor necrosis factor treatment in Crohn's disease: a prospective cohort study. Vermeire S, Noman M, Van Assche G, et al. Gastroenterology 2003 125 32 39 10.1016/S0016-5085(03)00701-7 12851868 (Pubitemid 36799104)
11. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF. Eriksson C, Engstrand S, Sundqvist KG, et al. Ann Rheum Dis 2005 64 403 407 15297281 (Pubitemid 40283050)
12. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Ferraccioli GF, Assaloni R, Perin A, Lancet 2002 360 645 12241963
13. Drug-induced lupus due to antitumor necrosis factor alpha agents. Costa MF, Said NR, Zimmermann B, Semin Arthritis Rheum 2008 37 381 387 10.1016/j.semarthrit.2007.08.003 17977585 (Pubitemid 351734520)
14. Autoimmunity and anti-TNF- agents. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P, Ann NY Acad Sci 2005 1051 559 569 10.1196/annals.1361.100 16126996 (Pubitemid 41362783)
15. Lessons for lupus from tumour necrosis factor blockade. De Bandt M, Lupus 2006 15 11 762 767 10.1177/0961203306071703 17153848
16. Anti-TNF therapy in rheumatoid arthritis and autoimmunity. Caramaschi P, Biasi D, Colombatti M, et al. Rheumatol Int 2006 26 3 209 214 Epub 2004 Dec 31 10.1007/s00296-004-0542-1 15627197 (Pubitemid 41830977)
17. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N, Arthritis Res Ther 2004 6 6 535 R543 Epub 2004 Sep 23 10.1186/ar1440 15535831
18. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Poulalhon N, Begon E, Lebbé C, et al. Br J Dermatol 2007 156 2 329 336 10.1111/j.1365-2133.2006.07639.x 17223874 (Pubitemid 46095962)
19. Complications and adverse reactions in the use of newer biologic agents. Callen JP, Semin Cutan Med Surg 2007 26 1 6 14 10.1016/j.sder.2006.12.002 17349557 (Pubitemid 46349778)
20. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. Scheinfeld N, J Dermatolog Treat 2004 15 5 280 294 10.1080/09546630410017275 15370396 (Pubitemid 39423287)
21. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. Lebwohl M, Bagel J, Gelfand JM, et al. J Am Acad Dermatol 2008 58 1 94 105 Epub 2007 Nov 5 10.1016/j.jaad.2007.08.030 17980456 (Pubitemid 350302037)
22. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Ramos-Casals M, Brito-Zerán P, Mũoz S, et al. Medicine (Baltimore) 2007 86 4 242 251 10.1097/MD.0b013e3181441a68 (Pubitemid 47067483)
23. Drug-induced lupus erythematosus [published retraction appears in Autoimmunity. 2008;41(3):241]. Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A, Autoimmunity 2005 38 7 507 518 10.1080/08916930500285857 16373256 (Pubitemid 43101785)
24. Club Rhumatismes et Inflammation: systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. De Bandt M, Sibilia J, Le Lot X, et al. Arthritis Res Ther 2005 7 3 545 R551 Epub 2005 Mar 1 10.1186/ar1715 15899041
25. Drug-induced lupus: an update. Vasoo S, Lupus 2006 15 11 757 761 10.1177/0961203306070000 17153847
26. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rosso A, J Clin Rheumatol 2005 11 1 47 49 10.1097/01.rhu.0000152148.55133.ba 16357696 (Pubitemid 40223880)
27. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Hochberg MC, Arthritis Rheum 1997 40 9 1725 9324033
28. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Gastroenterology 2004 126 1 19 31 10.1053/j.gastro.2003.10.047 14699483 (Pubitemid 38040720)
29. Lupus erythematosus. Sontheimer RD, Provost TT, Costner MI, Sontheimer RD, Provost TT, Cutaneous Manifestations of Rheumatic Diseases Philadelphia: Lippincott Williams & Wilkins, Sontheimer RD, Provost TT, 2004 15 64
30. Tumor necrosis factor- inhibitor-induced lupus-like syndrome presenting as fever of unknown origin in a liver transplant recipient: case report and concise review of the literature. Page AV, Liles WC, Transplant Proc 2008 40 5 1768 1770 10.1016/j.transproceed.2008.03.102 18589191 (Pubitemid 351853167)